Long-Term Treatment With Pegvisomant: Observations From 2090 Acromegaly Patients in ACROSTUDY.

European Journal of Endocrinology - United Kingdom
doi 10.1530/eje-18-0616
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bioscientifica

Related search

Glucose Homeostasis and Safety in Patients With Acromegaly Converted From Long-Acting Octreotide to Pegvisomant

Journal of Clinical Endocrinology and Metabolism
BiochemistryEndocrinologyClinical BiochemistryMedicineMetabolismDiabetes
2005English

Combined Treatment for Acromegaly With Long-Acting Somatostatin Analogs and Pegvisomant: Long-Term Safety for Up to 4.5 Years (Median 2.2 Years) of Follow-Up in 86 Patients

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2009English

Combined Treatment With Octreotide LAR and Pegvisomant in Patients With Gigantism - Acromegaly: Clinical Evaluation and Genetic Screening

Endocrine Abstracts
2016English

Long-Term Treatment of Acromegaly and Gigantism With Octreotide (SMS 201-995)

Folia Endocrinologica Japonica
1992English

Acromegaly: The Disease, Its Impact on Patients, and Managing the Burden of Long-Term Treatment

International Journal of General Medicine
Medicine
2013English

Efficacy and Safety of Monotherapy by Pegvisomant, a Growth Hormone Receptor Antagonist, in Japanese Patients With Acromegaly

Endocrine Journal
EndocrinologyMetabolismDiabetes
2016English

Pegvisomant in Combination With Long-Acting Somatostatin Analogues in Acromegaly: The Role of the GH Receptor Deletion of Exon 3

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2015English

Long-Term Results of Infertility Treatment in Patients With Endometriomas

2018English

Long-Term Data on Sirolimus Treatment in Patients With Lupus Nephritis

Oncotarget
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy